Methods and compositions for treating and preventing arthritis
Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.
1. A synergistic composition consisting of a therapeutically effective amount of carvacrol, a therapeutically effective amount of curcumin, a therapeutically effective amount of epigallocatechin-3-gallate, a therapeutically effective amount of oligomeric procyanidins, and a pharmaceutically acceptable carrier, wherein the carvacrol, curcumin, epigallocatechin-3-gallate, and oligomeric procyanidins are present in a molar ratio of 1:1:100:50 or a weight ratio of 10:10:1:10.
2. The composition of claim 1 , wherein the therapeutically effective amount of carvacrol is 1 the therapeutically effective amount of curcumin is 1 the therapeutically effective amount of epigallocatechin-3-gallate is 100 and the therapeutically effective amount of oligomeric procyanidins is 50 μg/ml.
3. The composition of claim 1 , wherein the therapeutically effective amount of carvacrol is 50 mg/kg, the therapeutically effective amount of curcumin is 50 mg/kg, the therapeutically effective amount of epigallocatechin-3-gallate is 5 mg/kg, and the therapeutically effective amount of oligomeric procyanidins is 50 mg/kg.
4. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is a phosphate buffered saline solution.
5. The composition of claim 1 , wherein the pharmaceutically acceptable carrier encapsulates the composition in an enteric coating.
6. The composition of claim 1 , wherein the pharmaceutically acceptable carrier encapsulates the composition in a nano-capsule.